Edition:
United States

CSL Ltd (CSL.AX)

CSL.AX on Australia Stock Exchange

123.50AUD
24 Mar 2017
Change (% chg)

$1.13 (+0.92%)
Prev Close
$122.37
Open
$123.52
Day's High
$125.28
Day's Low
$123.13
Volume
764,340
Avg. Vol
1,089,034
52-wk High
$126.00
52-wk Low
$91.62

Latest Key Developments (Source: Significant Developments)

CSL upgrades NPAT expectation for FY2017
Wednesday, 18 Jan 2017 05:09pm EST 

CSL Ltd : Upgraded its net profit after tax (NPAT) expectation for FY2017 . Now expects to deliver NPAT growth for FY17 in range of approximately 18% to 20% at constant currency on FY16 result . Expects to report NPAT of approximately US$800 million for six months ended 31 December 2016 .Expected result includes a currency exchange headwind of approximately US$20 million.  Full Article

CSL Ltd says AFSTYLA receives European Commission approval
Sunday, 8 Jan 2017 05:13pm EST 

CSL Ltd : European commission granted marketing authorisation for CSL Behring's AFSTYLA .Csl ltd -authorisation for children and adults with haemophilia A.  Full Article

CSL Behring says AEGIS-I study met its co-primary safety endpoints
Tuesday, 15 Nov 2016 01:25pm EST 

CSL Behring: CSL Behring presents positive results from the CSL112 AEGIS-I phase 2B trial . AEGIS-I study met its co-primary safety endpoints . AEGIS-I study showed that CSL112 is well-tolerated when administered in acute myocardial infarction (MI) setting .Study also provided confirmation of CSL112'S unique mechanism of action, cholesterol efflux enhancement.  Full Article

CSL closed new US$550 mln private placement in US
Thursday, 13 Oct 2016 06:54pm EDT 

CSL Ltd : On 13 October 2016 it closed a new USD550 million private placement in US . Private placement has a weighted average interest rate of 3.0% and an average life of 12.5 years . New facility was for AUD350 million bank facility and has a three year maturity .Proceeds from new debt raisings will be used to fund group's capital management plan and for general corporate purposes.  Full Article

CSL Behring says Japan's Ministry of Health, Labour and Welfare approved Idelvion
Thursday, 29 Sep 2016 09:46am EDT 

CSL Behring:Japan's Ministry of Health, Labour and Welfare has approved Idelvion.  Full Article

FDA accepts CSL Behring's Biologics license application
Tuesday, 30 Aug 2016 09:00am EDT 

Csl Ltd :Fda accepts CSL Behring's Biologics license application for first subcutaneous Prophylactic therapy to prevent hereditary Angioedema attacks.  Full Article

CSL Ltd to consider A$500 mln share buyback
Tuesday, 16 Aug 2016 06:27pm EDT 

CSL Ltd : 2016 FY results announcements and analysts briefing . Says "CSL board to consider further share buyback of A$500 million" . fy17 CSL group's net profit after tax (NPAT) is expected to grow approximately 11% at constant currency . "Earnings per share (EPS) are again expected to exceed profit growth" . "EBITDA is expected to grow approximately 14% this financial year" . "Turnaround of Seqirus is on track and is expected to breakeven in FY 2018" . Seqirus is expected to report a loss in the current fiscal year .  Full Article

CSL Ltd FY net profit after tax down 10 pct
Tuesday, 16 Aug 2016 06:25pm EDT 

CSL Ltd : Appendix 4e, directors report and financial statements . FY net profit after tax for the year attributable to members of the parent entity down 10.0% to US$1.24 billion . FY total revenue and other income US$ 6.13 billion versus US$5.63 billion . Final dividend of US$0.68 per ordinary share, unfranked, for year ended 30 June 2016 . During the year, the group carried out an on-market share buyback of up to A$1 billion as an element of its capital management program . During hy2017, CSL intends to approach US private placement market to raise about US$500 million as part of co's overall capital management program .  Full Article

CSL says US food and drug administration approved AFSTYLA
Wednesday, 25 May 2016 07:19pm EDT 

CSL Ltd : US food and drug administration (FDA) has approved AFSTYLA .Says afstyla is expected to be available in the US early this US summer.  Full Article

CSL announces FDA approval of its influenza vaccine
Monday, 23 May 2016 06:48pm EDT 

CSL Ltd : Flucelvax quadrivalent (influenza vaccine) - FDA approval . US food and drug administration (FDA) has approved seqirus' flucelvax quadrivalenttm .  Full Article

More From Around the Web

BRIEF-Momenta Pharmaceuticals announces HSR clearance

* Momenta Pharmaceuticals announces Hart-Scott-Rodino clearance for collaboration and license agreement with CSL